Global Parkinson's Disease Treatment Market to Reach $8 Billion by 2030
The global market for Parkinson's Disease Treatment estimated at US$4.9 Billion in the year 2022, is projected to reach a revised size of US$8 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2022-2030. Levodopa / Carbidopa, one of the segments analyzed in the report, is projected to record 8% CAGR and reach US$2.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Dopamine Receptor Agonists segment is readjusted to a revised 5.6% CAGR for the next 8-year period.The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 10.2% CAGR
The Parkinson's Disease Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.1% and 5.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.Select Competitors (Total 42 Featured) -
- AbbVie
- Acadia
- Boehringer Ingelheim
- Dr. Reddy’s
- GSK
- Impax
- Lundbeck
- Merck
- Novartis
- Sun Pharma
- Teva
- UCB
- US WorldMeds
- Valeant Pharmaceuticals
- Wockhardt
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Parkinson's Disease Treatment - Global Key Competitors Percentage Market Share in 2021 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2021 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Parkinson's Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Parkinson's Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Levodopa / Carbidopa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Levodopa / Carbidopa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for Levodopa / Carbidopa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Dopamine Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Dopamine Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Dopamine Receptor Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for MAO-Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for MAO-Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 12: World 16-Year Perspective for MAO-Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for COMT-inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for COMT-inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 15: World 16-Year Perspective for COMT-inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 16: World Recent Past, Current & Future Analysis for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 17: World Historic Review for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 18: World 16-Year Perspective for Anticholinergics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 20: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 21: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 22: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 23: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 24: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 25: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 26: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 27: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 28: World Parkinson's Disease Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
UNITED STATES
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 29: USA Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: USA Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 31: USA 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 32: USA Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: USA Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 34: USA 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2023 & 2030
CANADA
- Table 35: Canada Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Canada Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: Canada 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 38: Canada Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Canada Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: Canada 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2023 & 2030
JAPAN
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 41: Japan Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Japan Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: Japan 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 44: Japan Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: Japan Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: Japan 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2023 & 2030
CHINA
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 47: China Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: China Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: China 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 50: China Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: China Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: China 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2023 & 2030
EUROPE
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 53: Europe Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for Parkinson's Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: Europe 16-Year Perspective for Parkinson's Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: Europe Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: Europe 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 59: Europe Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: Europe Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: Europe 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2023 & 2030
FRANCE
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 62: France Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: France Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: France 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 65: France Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: France Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 67: France 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2023 & 2030
GERMANY
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 68: Germany Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Germany Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 70: Germany 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 71: Germany Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Germany Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 73: Germany 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2023 & 2030
ITALY
- Table 74: Italy Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Italy Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 76: Italy 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 77: Italy Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: Italy Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 79: Italy 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2023 & 2030
UNITED KINGDOM
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 80: UK Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: UK Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 82: UK 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 83: UK Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: UK Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 85: UK 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2023 & 2030
SPAIN
- Table 86: Spain Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Spain Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 88: Spain 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 89: Spain Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Spain Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 91: Spain 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2023 & 2030
RUSSIA
- Table 92: Russia Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Russia Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 94: Russia 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 95: Russia Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Russia Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 97: Russia 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2023 & 2030
REST OF EUROPE
- Table 98: Rest of Europe Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 99: Rest of Europe Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 100: Rest of Europe 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 101: Rest of Europe Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 102: Rest of Europe Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 103: Rest of Europe 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2023 & 2030
ASIA-PACIFIC
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 105: Asia-Pacific Historic Review for Parkinson's Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 106: Asia-Pacific 16-Year Perspective for Parkinson's Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
- Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 108: Asia-Pacific Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 109: Asia-Pacific 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2023 & 2030
- Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 111: Asia-Pacific Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 112: Asia-Pacific 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2023 & 2030
AUSTRALIA
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
LATIN AMERICA
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
MIDDLE EAST
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
AFRICA
- Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- Acadia
- Boehringer Ingelheim
- Dr. Reddy’s
- GSK
- Impax
- Lundbeck
- Merck
- Novartis
- Sun Pharma
- Teva
- UCB
- US WorldMeds
- Valeant Pharmaceuticals
- Wockhardt
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 93 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 4.9 Billion |
Forecasted Market Value ( USD | $ 8 Billion |
Compound Annual Growth Rate | 6.3% |
Regions Covered | Global |